Project Grant F32CA294934
Award Date
12/25/24
Completion Date
7/31/27
Dollars Obligated
$148K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
This Project Grant award, funded by the National Cancer Institute under the Cancer Research Manpower (CFDA 93.398) program, aims to elucidate the role of thiol reductive stress in lung cancer growth and metastasis. The $140,130 award to The General Hospital Corporation (Massachusetts General Hospital) will support research to investigate how the precise induction of reductive stress, regulated by the transcriptional regulator NRF2, impacts mitochondrial metabolism and contributes to the...
This $127,049 Project Grant award from the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program supports research by Harvard Medical School to investigate the functional and spatial properties of tumor-specific, tumor-infiltrating CD8 T cells. The key objectives are to: Generate patient-derived xenograft (PDX) mouse models of melanoma to test the required diversity of T cell receptors (TCRs) from tumor-infiltrating T cells to control tumor growth. Use one of...
This is a $1,593,000 federal Project Grant awarded by the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310). The grant was awarded on September 1, 2023 to The Children's Hospital Corporation, doing business as Boston Children's Hospital, a non-profit pediatric teaching hospital and research center. The funding supports a 3-year research project to "DEFINING THE UNIVERSAL GENOMIC LANGUAGE OF HALLMARKS IN TUMOR...
This $231,413 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research at Massachusetts General Hospital (MGH) to develop in vitro models that recapitulate the development of germ cell neoplasia in situ (GCNIS), the precursor to testicular germ cell tumors. The project aims to produce induced pluripotent stem cell-derived primordial germ cell-like cells and genetically engineer them or human testicular cancer cells to recreate the GCNIS...
This Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $665,155 to The Johns Hopkins University from September 2024 through August 2029 to elucidate the mechanisms connecting chronic stress and cancer metastasis. The project aims to investigate how glucocorticoids and the sympathetic nervous system drive metastasis, as well as how metastases impact the activity of the hypothalamic-pituitary-adrenal axis in a feedforward loop. This...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $415,257 to The Methodist Hospital Research Institute (HMRI) in Houston, Texas to investigate improving the efficacy of chimeric antigen receptor (CAR) T-cell cancer immunotherapies. The key objectives are to analyze the role of stress granules, which are cytoplasmic compartments that form in activated T cells, in CAR-T cell exhaustion and tumor control. The project will evaluate...
This $3,510,000 five-year Project Grant award under the National Cancer Institute's Cancer Biology Research (CFDA 93.396) program supports research by the Sanford Burnham Prebys Medical Discovery Institute to investigate the effects of aging on melanoma metastasis mechanisms. The research aims to define how key components of the unfolded protein response (UPR), such as the transcription factor ATF4, impact pro- and anti-apoptotic signaling in melanoma under conditions of aging. The project...
This $1,372,925 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research at Cold Spring Harbor Laboratory (CSHL) to investigate the central mechanisms underlying disrupted glucocorticoid circadian rhythms in breast cancer. The research aims to systematically determine where along the hypothalamic-pituitary-adrenal (HPA) axis the dysfunction occurs in response to breast cancer, identify the underlying mechanisms, and then use approaches to...
This $3,787,956 federal Project Grant award, issued by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), is funding a multi-year research program at New York University School of Medicine to investigate and target replication stress in small cell lung cancer (SCLC). The program aims to understand how the SLFN11 gene and replication stress response pathways regulate chemosensitivity in SCLC subtypes, and to develop strategies to combat acquired...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $2,880,937 to the Dana-Farber Cancer Institute, Inc. to conduct research aimed at improving survival for children with diffuse midline gliomas (DMG), an aggressive type of brain cancer. The research project tests the hypothesis that combining radiation therapy with drugs that target specific vulnerabilities in DMG cells can enhance the efficacy of radiotherapy. Key components include:...